预测低于标准血清酸度的临床诺莫图在中国患者中
Zi-Hao Duan1, Chun-Yuan He1, Jie Chen1
1Department of Pharmacy, Lu'an Affiliated Hospital of Anhui Medical University & Lu'an People's Hospital, Lu'an, Anhui, China.
Current therapeutic research, clinical and experimental
|February 3, 2025
概括
低于标准的血清酸 (VPA) 水平可能导致治疗失败. 这项研究开发了一种名谱,用于预测中国患者的低VPA度,改善治疗药物监测.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 低于标准的血清氨酸 (VPA) 度与治疗失败有关.
- 目前还没有一种快速的方法来预测低于最佳的VPA水平.
研究的目的:
- 确定导致中国患者血清VPA度低的因素.
- 为预测低于标准的VPA水平的风险开发一个名图.
主要方法:
- 从630名住院的中国患者中对1143名血清VPA度进行了回顾性分析.
- 后勤回归分析以确定不符合标准的VPA水平的影响因素.
- 开发和验证一个名ogram预测模型.
主要成果:
- 每日剂量,服用途径,肝病变,低蛋白血症和同时使用碳烯/巴比图拉酸是独立的危险因素.
- 开发的名图表显示出良好的准确性和区别性.
- 决策曲线分析表明,预测间隔宽,净收益显著.
结论:
- 为中国患者建立了一种低于标准的血清VPA度的新型诺米克风险预测模型.
- 这种工具有助于临床医生和患者迅速达到目标VPA度.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219
Antiepileptic Drugs: Potassium Channel Activators
142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
142
Antiepileptic Drugs: GABAergic Pathway Potentiators
316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
113
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
113
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
75
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
75


